title: Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model.
abstract: Angiotensin converting enzyme inhibitors (ACEI) are believed to protect remnant kidney, but all previous studies used the ligation model which causes severe hypertension, and very few have compared drugs in rats having similar control of blood pressure (BP). We compared rats with uremia obtained by 70% excision of total renal mass, a model which causes mild, late hypertension. Study I compared the effects of enalapril (E), cicletanine (C) and placebo (P) in uremic (U) rats fed a 0.50% (normal-high) Na diet. Study II compared the effects of E, C, P, and guanfacine (G) in U rats fed a diet restricted to 0.25% Na (normal-low). In study I, UP rats developed progressive hypertension (140, 146, 160 and 166 mm Hg at 3, 6, 9 and 12 weeks), proteinuria (240 mg/day at 9 and 12 weeks) which were not affected by E or C. The occurrence of end-stage renal disease (ESRD) led to the sacrifice of all rats after three months. All three groups had similar severe renal lesions (over 25% sclerosed glomeruli in 5 of 10 UP, 9 of 14 UE, 7 of 14 UC rats, with huge cystic tubular dilatations). In study II, rats could be sacrificed later (6 months) and had evidence of less severe renal disease. All the drugs tested prevented hypertension throughout the study (P less than 0.001), with lowest values in UE rats. E and G, but not C, reduced proteinuria. Renal damage was reduced with E and G, but not with C, despite similar BP in C and G rats. Thus, in contrast with what was obtained in the ligation model, ACEI affected neither the BP nor the renal lesions of rats made uremic by renal excision and fed a 0.50% Na diet. Moderate Na restriction improved the consequences of nephron loss and restored the anti-hypertensive effect of drugs. However, these drugs had a different effect on renal preservation: it was dramatic with E, good with G, and undetectable with C.
authors.affiliation: INSERM U. 192, Hôpital Necker Enfants-Malades, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Terzi
authors.forename: H
authors.initials: H
authors.lastname: Beaufils
authors.forename: D
authors.initials: D
authors.lastname: Laouari
authors.forename: M
authors.initials: M
authors.lastname: Burtin
authors.forename: C
authors.initials: C
authors.lastname: Kleinknecht
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004232:Diuretics / Q000627:therapeutic use; D004656:Enalapril / Q000627:therapeutic use; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009392:Nephrectomy; D011725:Pyridines; D051381:Rats; D017208:Rats, Wistar; D012982:Sodium, Dietary / Q000008:administration & dosage*; D014511:Uremia / Q000188:drug therapy / Q000209:etiology / Q000473:pathology
chemical_list: D000959:Antihypertensive Agents; D004232:Diuretics; D011725:Pyridines; D012982:Sodium, Dietary; D004656:Enalapril; C038068:cicletanine